Acute myeloid leukemia in adults: Where do we go from here?

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue SUPPL. 1, 2001, Pages

  Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Hematopoietic growth factors; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE DISEASE; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 17044461792     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100304     Document Type: Article

References (46)

1. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240
2. Archimbaud E, Ottmann OG, Liu-Yan JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewan C, Matcham J, Hoelzer D (1999) A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94:3694
3. Arlin Z, Case DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K, the Lederle Cooperative Group (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177
4. Baer MR, George SL, Dodge RK, Cooke K, Caligiuri AM, Powell BL, Kolitz JE, Schiffer CA, Larson RL (1999) Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) ≥60 years (CALGB 9720). Blood 94 [Suppl 1]:383a
5. Bensinger WI, Deeg HJ (2000) Blood or marrow? Lancet 355:1231
6. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 15:1666
7. Bhalla K, Birkhofer M, Arlin A, Grant S, Lutzky J, Graham G (1988) Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2:810
8. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710
9. Blair A, Hogge DE, Sutherland HJ (1998) Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/ HLA-DR-. Blood 92:4325
10. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Mayer RJ (1998) Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173
11. Burnett AK, Goldstone AH, Stevens RM, Hamm IM, Rees JKH, Gray RG, Wheatley K, for the UK Medical Research Council Adult and Children's Leukemia Working Parties (1998) Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 351:700
12. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649
13. Childs R, Chernoff A, Contentin N, Baceci E. Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
14. Dombret H, Yver A, Chastang C, Degos L, for the Cooperative Study Group (1995) Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration after intensive induction chemotherapy in elderly patients with de novo acute myeloid leukemia (AML): final results of a randomized multicenter double-blind controlled study. N Engl J Med 332:1678
15. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3
16. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Guttermann J, Deisseroth A, Keating M (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246
17. Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B (1986) Evidence for differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 315:15
18. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR (1998) A double blind placebo controlled trial of granulocyte colony stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 91:3607
19. Greenberg P, Advani R, Tallman M, Letendre L, Saba H, Dugan K, Lee SJ, Lum B, Sikic B, Paietta E, Bennett J, Rowe JM (1999) Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase III trial (E2995). Blood 94 [Suppl 1]:383a
20. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, Francois S, Briere J, Guyotat D, Cassassus P, Audhuy B, Tellier Z, Hurteloup P, Herve P (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90:2978
21. Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M, Guilhot F, Le Prise PY, Abgrall JF, Deconinck E, Guyotat D, Vilque JP, Casassus P, Tournilhac O, Audhuy B, Solary E (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18:780
22. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A, for The International Acute Myeloid Leukemia Study Group (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710
23. Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Velez-Garcia E, Powell B, Moore J, Caligiuri M, Vardiman J, Bloomfield CD, Larson RL (1999) Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid (AML) <60 years old: preliminary results of CALGB 9621. Blood 94 [Suppl 1]:384a
24. Lee EJ, George ST, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Didge, RK, Smith R, Baer M, Schiffer CA (1999) Parallel phase I studies of daunorubicin given with cytosine arabinoside and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients ≥60 years of age with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol 17:2831
25. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89:3323
26. Lowenberg B, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmur J, Gratwohl A, Hess U, Fey MF, van Putten WLJ (1997) Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496
27. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-111, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group. Blood 90:2952
28. Mayer RF, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, for the Cancer and Leukemia Group B (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896
29. Nucifora G, Larson RA, Rowley JD (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712
30. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayma S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871
31. Peterson BA, George SL, Bhalla K, Lee E, Carpenter JT, Berk GI, Schiffer CA (1996) A phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia. Proc Am Soc Clin Oncol 15
32. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ (1996) Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428
33. Ross DD, Thompson BW, Joneckis CC, Akman SA, Schiffer CA (1986) Metabolism of Ara-C by blast cells from patients with ANLL. Blood 68:76
34. Rowe JM, Andersen J, Mazza JJ, Paietta E, Bennett JM, Hayes A, Oette D, Wiernik PH (1995) Phase III randomized placebo-controlled study on granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55-70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 86: 257
35. Schiffer CA (1996) Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675
36. Schiffer CA, Dodge R, Larson RA (1997) Long-term follow-up of CALGB studies in acute myeloid leukemia. Cancer 80: 2210
37. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM (2000) A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95:2530
38. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith F, O'Shannon-Dorcy K, Berger MS, Bernstein ID (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678
39. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA, for the Cancer and Leukemia Group B (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671
40. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura G (1992) A phase-three trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia. A Southeastern Cancer Group Study. J Clin Oncol 10:1103
41. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88:2841
42. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313
43. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY, Gardin C, Lioure B, Witz B, Francois S, Desablens B, Pignon B, Leprise PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL (1998) A placebo controlled study of recombinant human granulocyte-macrophage colony stimulating factor during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 91:2722
44. Woods WG, Neudorf S, Gold S, Sanders J, Kobrinsky N, Barnard D, DeSwarte J, Arthur D, Lange BJ (1996) Aggressive post-remission (REM) chemotherapy is better than autologous bone marrow transplantation (BMT) and allogeneic BMT is superior to both in children with acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 15:368a
45. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217
46. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150